Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker se

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker se

Item

http://www.wikidata.org/entity/Q44020318

Q44020318

about

Biologic complexity in sickle cell disease: implications for developing targeted therapeutics Drugs for preventing red blood cell dehydration in people with sickle cell disease Drugs for preventing red blood cell dehydration in people with sickle cell disease Genomic approaches to identifying targets for treating β hemoglobinopathies Ion channels and transporters in tumour cell migration and invasion GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease New insights on hereditary erythrocyte membrane defects 2015 Clinical trials update in sickle cell anemia Epigenetic dysregulation of KCa 3.1 channels induces poor prognosis in lung cancer.Stroke in patients with sickle cell disease.Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model.Treating sickle cell disease by targeting HbS polymerization NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.A GCH1 haplotype confers sex-specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia.Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom.Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.Mutations in the Gardos channel (KCNN4) are associated with hereditary xerocytosis.Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore.'Gardos Channelopathy': a variant of hereditary Stomatocytosis with complex molecular regulation The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype).Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.A non-electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease.N-ethylmaleimide activates a Cl(-)-independent component of K(+) flux in mouse erythrocytes The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe Current management of sickle cell anemia.IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.Tissue resident memory T cells in the human conjunctiva and immune signatures in human dry eye disease.Ion channel drug discovery: challenges and future directions.Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.The CNS under pathophysiologic attack--examining the role of K₂p channels.The trials and hopes for drug development in sickle cell disease.Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.Minireview: Genetic basis of heterogeneity and severity in sickle cell disease.Emerging point-of-care technologies for sickle cell disease screening and monitoring.KCa 3.1-a microglial target ready for drug repurposing?Advances in understanding the pathogenesis of the red cell volume disorders.

P2860

Q21284789-4885B0EE-91C9-4A8A-A650-1EFB14E6BA62 Q24186046-072F288E-B084-4D83-A418-4EE3C97DC203 Q24202032-6481F6E0-09F7-4AF8-82AC-A5014034E7E8 Q26799214-2A1499A2-44DE-4B07-BAAA-E1B6A321ADDD Q26849490-F4C7B7B7-981C-4D98-BB9C-16F61C99D7D0 Q27716374-3FF7986F-6A09-41B5-89FB-27511FC0CD65 Q28076162-658FD744-F558-494C-A0EA-44EAACD1EFD6 Q28086979-9FC3C298-E61B-44D9-B56A-2EF2BE2A78A1 Q30316755-2E1F81B4-64F6-477C-9B6D-4C773ABE22DD Q30650303-C276249B-23BD-47B9-9A57-7C4D8AD7EC4D Q33670161-F725566C-272B-4999-BCA9-82CD841A8B70 Q33707352-E2F185F6-1FBC-49F4-8A74-AD966BEEB622 Q34293957-07AA3735-875D-4C08-B819-4A7707432B6B Q34796372-D1BAB00F-F893-4793-94B0-FE16EA24E135 Q35243386-1B0BFC98-3D14-4E8D-ACCB-B43FD97F6B59 Q35549141-27128C69-D10A-4E8E-B41D-D5D03EA7E1E8 Q35660234-16FA167C-3B1C-4279-9178-94F802804CEE Q36051078-506EEDEC-B23B-473B-B027-0258B0B2E3CE Q36261948-3F270748-8F37-4ECA-B12D-0818761D780C Q36369767-9D52B8F3-3587-4CDB-9572-6E2A0B7D1B4B Q36438976-1BDC3367-304E-4593-A427-2ABC83218850 Q36540959-E17FE563-5031-4CC2-AF87-9FAA1D616039 Q36596855-A24BDD1F-72CE-4794-A1F5-E79D6D90FCC8 Q36713158-53504D0B-F8FC-4BEC-9682-FF68AB195900 Q36823889-B47635F4-B7B1-4EB8-92C4-073224A6C958 Q36862364-1FB3F0B1-C3BC-46AC-BB0F-DF7CD6AA4047 Q37040238-E2862DBB-2872-48E7-8F89-E72CB0CAAFD7 Q37291510-EA9D4216-0212-4873-8778-0285EE0AE6F6 Q37327602-173FF75D-E017-4A51-B26E-06E01417C491 Q37409003-4C559338-A2CC-4A9C-9E63-7CC11178F1AE Q37721598-276CE332-DFFC-4D44-94FE-D1E64B52831C Q37998135-3DC7D4EB-CC49-42EB-9F72-F48C760B8044 Q38056312-0667EB0B-EAB8-48B1-B8E8-D9CD62271982 Q38284426-B246153C-94E4-43DE-B87C-F159A087C533 Q38540335-8AEF7D08-27F8-4ADB-B1BC-BC398C7069C5 Q38685245-E5DDF995-EE0B-48E8-91E4-23F492F281E4 Q38758451-A71E80B9-224A-4189-8E75-F8B07DA3F156 Q38804432-43737F6D-3867-4956-B87D-86C457CE2442 Q38819263-3FAA4030-E3C4-4238-9FDE-16C712AF8A80 Q38880050-F0C855E0-23F0-4604-BDCC-03C1732D7B8C

P2860

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker se

Item

http://www.wikidata.org/entity/Q44020318

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Improvements in haemolysis and ...... the Gardos channel blocker se

@en

Improvements in haemolysis and ...... the Gardos channel blocker se

@nl

type

Item

label

Improvements in haemolysis and ...... the Gardos channel blocker se

@en

Improvements in haemolysis and ...... the Gardos channel blocker se

@nl

prefLabel

Improvements in haemolysis and ...... the Gardos channel blocker se

@en

Improvements in haemolysis and ...... the Gardos channel blocker se

@nl

P1476

Improvements in haemolysis and ...... the Gardos channel blocker se

@en

P2093

Abdullah Kutlar

http://www.w3.org/2001/XMLSchema#string

Carolyn Bigelow

http://www.w3.org/2001/XMLSchema#string

Frederic Galacteros

http://www.w3.org/2001/XMLSchema#string

ICA-17043-10 Study Investigators

http://www.w3.org/2001/XMLSchema#string

James H Hull

http://www.w3.org/2001/XMLSchema#string

Jonathan W Stocker

http://www.w3.org/2001/XMLSchema#string

Kenneth I Ataga

http://www.w3.org/2001/XMLSchema#string

Luther St James

http://www.w3.org/2001/XMLSchema#string

Marvin Reid

http://www.w3.org/2001/XMLSchema#string

Samir K Ballas

http://www.w3.org/2001/XMLSchema#string

P2860

A human intermediate conductance calcium-activated potassium channel

Sickle-cell disease

Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells.

Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.

Sickle red cell adhesion: many issues and some answers.

No NO, no pain? The role of nitric oxide and cGMP in spinal pain processing.

Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives.

ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.

P304

92-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2010.08520.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49838574

http://www.w3.org/2001/XMLSchema#string

P698

21323872

http://www.w3.org/2001/XMLSchema#string

P921

patient

sickle-cell disease

placebo

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker se

about

P2860

P2860

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker se

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921